VCs Put $15M Into New Start-Up From Proteolix Founder
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech, Arvinas, will pursue therapies that degrade proteins, a process that could lead to therapeutic approaches to targets previously thought to be undruggable. The $15 million in venture funding is augmented by $3.5 million from the state of Connecticut.
You may also be interested in...
Arvinas Finds First Partner For Protein-Degradation Technology In Merck
Arvinas’ proprietary work has been in oncology, with a prostate cancer candidate slated to enter the clinic in 2016, but the collaboration with Merck will focus on a variety of targets and therapeutic areas.
Financings Of The Fortnight Wonders How Wide-Open Is The Window?
The beginnings of ominous signs are appearing in the flourishing biotech IPO market. Plus news on recent financings by Foundation Medicine, Arvinas, Moderna Therapeutics and Frazier Healthcare.
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.